The DevelopAKUre Project: Exceeding Recruitment Goals

Discover how Ergomed successfully recruited 140 patients with Alkaptonuria (AKU)—a rare genetic disorder affecting only 350 known patients in Europe—in just 9 months.

 
This Phase II/III Repurposing Study, funded by a European FP7 grant, aimed to repurpose drugs for AKU with a focus on long-term patient follow-up. See how Ergomed collaborated with the AKU Society, developed an extensive online awareness campaign, and organized cross-border enrollment and travel support. Download the full case study to learn how Ergomed’s strategic outreach and patient-centered approach drove recruitment success in ultra-rare disease trials.  

Please fill out the form to view the content

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.